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Abstract. Systemic amyloidosis can be hereditary or acquired with autosomal dominant mutations in the transthyretin
gene (TTR) being the most common cause of hereditary amyloidosis. ATTRm amyloidosis is a multi-system disorder with
cardiovascular, peripheral and autonomic nerve involvement that can be difficult to diagnose due to phenotypic heterogeneity.
This review will focus on the neuropathic manifestations of ATTRm, the genotype-phenotype variability, the diagnostic







There are more than 30 proteins that can cause13
localised or systemic amyloidosis; 12 of which14
acquire amyloidogenicity from a germline mutation15
(Table 1 outlines the characteristics of the more16
common amyloidogenic proteins). Of the hereditary17
amyloidosis, transthyretin (TTR) is the most preva-18
lent subtype with more than 100 pathogenic TTR19
mutations reported to date. TTR is amyloidogenic20
in both wild-type and hereditary forms (ATTRwt21
and ATTRm are the approved nomenclature for22
wild type and hereditary ATTR amyloidosis, respec-23
tively) [8]. TTR is primarily synthesized in the liver24
and is a 127-residue homotetrameric protein that25
carries thyroxine and retinol-binding protein [1].26
Dissociation of TTR followed by aggregation and27
misfolding of the oligomers and monomers causes28
formation of insoluble amyloid fibrils which deposit29
systemically resulting in peripheral and/or autonomic30
neuropathy, and other systemic manifestations,31
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particularly cardiomyopathy [9]. Significant progress 32
in the treatment of ATTRm has been made with excit- 33
ing developments in gene silencing therapies. This 34
review will discuss the clinical features of ATTRm 35
neuropathy and highlight therapeutic developments 36
in the field. 37
CLINICAL PRESENTATION OF ATTRm 38
ATTRm amyloidosis is a rare disease with diverse 39
clinical manifestations that is in part determined by 40
the genotype. Given this complexity, there can be 41
a delay in diagnosis of up to 4 years from symp- 42
tom onset for patients with ATTRm presenting with 43
a peripheral neuropathy and up to 8 years for patients 44
presenting with a cardiomyopathy [13]. Carpal tun- 45
nel syndrome (CTS) can be the initial symptom in 46
up to 33% of patients with a mean period of 4–6 47
years before other organs are clinically involved [14]. 48
Patients then usually develop a peripheral and auto- 49
nomic neuropathy, and often cardiac involvement. As 50
TTR is also produced within the choroid plexus and 51
the epithelium of the retina, central nervous system 52
(CNS) manifestations can also rarely occur, and are 53
more common for some disease-causing mutations 54
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Precursor protein Organ Involvement Treatment
Peripheral Nervous Autonomic Nervous Heart Kidney Liver GIT Eyes Tongue
System System





++ ++ +++ +++ ++ ++ – +++ Chemotherapy/
ASCT
ATTRm Hereditary Mutations in TTR
gene






ATTRwt Acquired Wild-type TTR + – +++ – – – – – Supportive
AA Acquired Inflammatory
disorders
SAA – ++ +/– (late) +++ +(Late) + – +/– Suppression of
inflammation
AFib Hereditary Mutations in
fibrinogen -chain
gene
Mutant fibrinogen – – +/– +++ +/– – – – Supportive, organ
transplant
AAPoA1 Hereditary Mutations in
apolipoprotein A1
gene
MutantApoA1 + – + ++ ++ – – – Supportive, organ
transplant
ALys Hereditary Mutations in
lysozyme gene
Mutant lysozyme – – +/– +++ ++ ++ – – Supportive, organ
transplant
AGel Hereditary Mutations in
gelsolin gene





2M – (CTS) – +/– – +/– – – – Supportive, renal
transplant
Abbreviations: AA = amyloid A, AApoA1 = apolipoprotein A1 amyloid, A2M =2-microglobulin amyloid, AFib = fibrinogen A -chain amyloid, AGel = gelsolin amyloid, AL = amyloid light
chain, ALys = lysozyme amyloid. ASCT = autologous stem cell transplant, ATTR = amyloid transthyretin, CTS- Carpal tunnel syndrome, GIT = Gastrointestinal, SAA = serum amyloid A. +++
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that have a predilection for the CNS, such as55
ATTRL12P [15, 16].56
Peripheral neuropathy57
V30M is the most common ATTR mutation58
worldwide and is endemic in Portugal, Japan and59
Sweden [17]. The early-onset phenotype, with onset60
in the 20s to 40s, was first described in Portu-61
gal and was previously known as familial amyloid62
polyneuropathy (FAP). Patients initially present with63
a length-dependent, painful, small-fibre neuropathy64
progressing over time to a generalised sensorimo-65
tor neuropathy. In contrast, cases from non-endemic66
areas, and late-onset presentations of many muta-67
tions may present with involvement of all sensory68
modalities. Some mutations have a faster disease pro-69
gression than ATTRV30M, such as the ATTRL55P70
where patients may present with a peripheral neu-71
ropathy as early as 19 years of age and die within 372
to 8 years [18]. Amyloidosis can also present atyp-73
ically as an upper-limb predominant neuropathy a74
radiculopathy or a myopathy [5–7].75
Autonomic neuropathy76
ATTRm amyloidosis often involves early auto-77
nomic involvement and overall, up to 75% of patients78
with ATTRm develop symptoms of an autonomic79
neuropathy, affecting the cardiac, gastrointestinal,80
and genitourinary systems [19]. Autonomic symp-81
toms can be very disabling with a high morbidity82
and the most worrying autonomic manifestation is83
arrhythmias and sudden death has been reported.84
The severity of cardiovascular autonomic impairment85
is unrelated to the severity of the peripheral neu-86
ropathy. Orthostatic hypotension is a troublesome87
symptom that can present with non-specific symp-88
toms of fatigue, reduced exercise tolerance and vague89
dizziness. Gastrointestinal symptoms caused by amy-90
loid infiltration of the mesenteric plexus include91
gastroparesis, dysmotility, constipation and diarrhoea92
(often nocturnal initially). Genitourinary dysfunction93
can include urinary retention, nocturia, incomplete94
emptying and frequency; erectile dysfunction is very95
common in male patients. Pupillomotor and sudomo-96
tor functions can also be impaired [20].97
Other systemic manifestations98
Certain TTR mutations primarily cause cardiac99
amyloidosis, the most common worldwide being100
ATTRV122I, which is present in approximately 4% 101
of African Americans and causes a restrictive car- 102
diomyopathy. ATTRT60A can present with cardiac 103
involvement alone but with time both cardiac and 104
peripheral nerve involvement is common. Cardiomy- 105
opathy is more common with late-onset ATTRV30M 106
cases than the classic early-onset presentation [21]. 107
Oculoleptomeningeal amyloidosis, associated with, 108
but not limited to, ATTRL12P can present with a 109
range of neurological signs and symptoms includ- 110
ing headaches, seizures, subarachnoid haemorrhage, 111
and hearing or visual loss [15]. Ocular abnormal- 112
ities including vitreous deposits are reported in 113
approximately 10% of patients with ATTRV30M. 114
Significant, unexplained weigh loss of more than 115
10% of bodyweight is a common manifestation of 116
systemic amyloidosis [5]. 117
Other hereditary amyloidosis that can cause 118
neuropathies 119
Mutations in ApoA1 gene have been associated 120
with systemic amyloidosis mainly causing renal fail- 121
ure. However, one mutation, AApoAIG26R, can 122
cause a length-dependent, sensorimotor neuropathy 123
similar to the neuropathy associated with ATTRm 124
[22]. Gelsolin related amyloidosis (also referred to 125
as Finnish type amyloidosis) initially presents as a 126
lattice corneal dystrophy followed by a progressive 127
cranial neuropathy causing bilateral facial weakness 128
[23]. 129
PHENOTYPIC VARIATIONS WITHIN 130
GENOTYPES 131
Penetrance 132
The development of disease-modifying treatments 133
raises questions about screening and timely access 134
to treatments. Hence, knowing the penetrance of 135
different mutations and the reasons for varying clin- 136
ical manifestations is relevant in clinical practice. 137
ATTRV30M amyloidosis has variable disease pen- 138
etrance depending on geographic location and age of 139
onset. In Sweden, where the age of onset is later than 140
in Portugal, penetrance of ATTRV30M is reported to 141
be less than 50%, compared with 80% penetrance in 142
the early-onset Portuguese population. Penetrance of 143
ATTRT60A is difficult to define as age of onset of 144
disease is in the 60s, and patients may die from other 145
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INVESTIGATIONS147
Diagnosing neuropathy148
Depending on the presenting symptoms, patients149
may see a range of physicians prior to a diagnosis150
of ATTRm amyloidosis. Neurologists are generally151
referred patients with symptoms suggestive of a152
peripheral neuropathy or those with a known diag-153
nosis of amyloidosis to be investigated for a clinical154
or subclinical neuropathy. Initially, patients may only155
have clinical features of a small fibre neuropathy156
(SFN), and conventional nerve conduction studies157
(NCS) may be normal. There are quantitative and158
qualitative methods to measure small fibre dysfunc-159
tion including quantitative sensory testing (QST),160
which is a psychophysical test of small fibre func-161
tion. Quantification of intraepidermal nerve fibres162
in a skin biopsy is the gold standard for diag-163
nosing SFN and has a sensitivity and specificity164
of around 90% [26]. As the peripheral neuropa-165
thy progresses, large fibres are affected. Classically,166
NCS demonstrate an axonal, sensorimotor, length-167
dependent neuropathy with frequent median nerve168
entrapment at the wrists. However, in both ATTRm169
and AL amyloidosis, slow conduction with prolonged170
distal motor latencies can be seen which may lead to171
a neurophysiological diagnosis of a demyelinating172
neuropathy and subsequently a clinical diagnosis of173
chronic inflammatory demyelinating polyneuropathy174
(CIDP) [27].175
Autonomic neuropathy176
Symptoms of autonomic dysfunction are a177
common feature of ATTRm related neuropathy.178
Autonomic function tests can help diagnose dysau-179
tonomia and investigate sudomotor, cadiovagal and180
adrenergic function using tests that assess physio-181
logic or neurochemical function in response to a182
change in the environment [28]. Cardiovagal func-183
tion is commonly assessed by quantifying the heart184
rate response to deep breathing and to the Val-185
salva manoeuvre, with a loss of heart rate variability186
suggesting cardiovagal dysfunction. This is com-187
plemented by the head-up tilt test and measuring188
plasma catecholamines in response to the tilt to test189
for orthostatic hypotension. An attenuated plasma190
catecholamines increase suggests sympathetic dys-191
function. Orthostatic hypotension is defined as a192
sustained reduction of systolic blood pressure of193
at least 20 mmHg or diastolic blood pressure of194
10 mmHg within 3 min of standing or head-up tilt 195
to at least 60 degrees on a tilt table [29]. Pupillome- 196
try, urodynamics and gastrointestinal motility studies 197
or manometry can be performed to assess autonomic 198
dysfunction in these organs [30]. 199
Investigate cause of neuropathy 200
If the clinical suspicion for ATTRm is high, for 201
example, if a patient has a painful, axonal neuropathy, 202
dominant family history, cardiac and/or autonomic 203
symptoms or an ethnicity with a high prevalence of 204
ATTRm, investigations for the cause of the neuropa- 205
thy may be very limited. ATTRm amyloidosis can be 206
excluded if genetic testing confirms wild-type TTR, 207
as sequence analysis of the gene detects more than 208
99% of pathogenic variants [31]. An online database 209
(http://www.amyloidosismutations.com/main menu. 210
html) provides an updated list of amyloidogenic 211
mutations and their phenotypes [24]. In the absence 212
of diabetes, the development of a neuropathy with 213
autonomic involvement should always raise the 214
possibility of amyloidosis. In more ambiguous 215
cases, a broad, routine approach to investigating 216
neuropathies may be taken, especially to exclude 217
acquired causes. 218
Amyloidosis is a histologic diagnosis; however, 219
a nerve biopsy is not always needed if the neuro- 220
logical phenotype is concordant with the diagnosis, 221
no other cause for a neuropathy is found and the 222
patient has a pathogenic mutation in the TTR gene. 223
In these cases, to diagnose systemic amyloidosis, 224
a less invasive method can be used such as sub- 225
cutaneous abdominal fat aspirate or labial salivary 226
gland biopsy, which have a sensitivity of 50–80% and 227
90%, respectively [2–4]. Sural nerve biopsies have a 228
sensitivity cited as high as 86%, but it can be dif- 229
ficult to confirm the diagnosis in any tissue due to 230
patchy deposition and repeated biopsies, or biopsies 231
from different sites may be required32. Congo-red 232
positive areas of the biopsy undergo immunohisto- 233
chemistry for typing of the amyloid protein (TTR vs. 234
other), and if this is equivocal, the biopsy undergoes 235
laser microdissection followed by mass spectrome- 236
try [33]. These tests to identify protein type can be 237
performed on any affected tissue including salivary 238
gland, nerve, rectal mucosa, endomyocardial biopsy 239
specimens and tenosynovial tissues obtained at carpal 240
tunnel release surgery. Sequencing of the TTR 241
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Systemic involvement of ATTRm244
Identifying the extent of amyloidosis is important245
for management and prognosis. There are specialised246
imaging modalities that are sensitive in identifying247
organ deposition and the pattern of uptake can pro-248
vide clues to the type of amyloid. Serum amyloid P249
(SAP) is a glycoprotein found in all types of amy-250
loid deposits. SAP scintigraphy uses radiolabelled251
SAP as a tracer to quantify and identify amy-252
loid deposition, but has poor visualisation of heart,253
peripheral nerve and the CNS. SAP scintigraphy has254
high sensitivity, 90%, in AA and AL amyloidosis255
[34], but only 48% in ATTR amyloidosis [35]. A256
radionuclide tracer with greater sensitivity in ATTR257
amyloidosis is 99 m-technetium-3,3, -diphosphono-258
1,2-propanodicarboxylic acid (99mTc-DPD). It has259
a sensitivity and specificity of identifying cardiac260
ATTR amyloid deposits of 91% and 82%, respec-261
tively [36].262
DIFFERENTIAL DIAGNOSES263
The most common misdiagnosis of amyloidosis264
affecting the peripheral nerves is CIDP as patients265
with ATTRm can have slowed conduction on neuro-266
physiology and raised CSF protein. In a study of 150267
patients with ATTRm, 42 (32%) had been misdiag-268
nosed, 30 (61%) of which were initially diagnosed269
as CIDP, and 2% as vasculitic neuropathy [37]. Out270
of the patients misdiagnosed as CIDP, seven patients271
fulfilled EFNS/PNS criteria for definite CIDP with272
conduction velocities as low as 33 m/s in the upper273
limbs. Also, as amyloid can have patchy deposition,274
it can also be misdiagnosed as a radiculopathy or275
plexopathy. As such there should be a high suspi-276
cion for ATTRm in patients diagnosed with CIDP277
that do not respond to immunomodulatory treatment278
[38]. AL-amyloidosis can also be difficult to dis-279
tinguish from ATTRm as both may initially present280
with isolated CTS and up to 65% of patients with281
AL-amyloidosis develop symptoms of an autonomic282
neuropathy [19]. The coexistence of monoclonal283
gammopathy of undetermined significance (MGUS)284
with ATTRm or ATTRwt is recognised, especially in285
older people, but not widely appreciated. In a study286
of 57 patients with ATTRV122I amyloidosis, aged287
between 50–90, median age 71 years, 49% had abnor-288
mal serum free light chain ratios and/or paraprotein289
on immunofixation, suggesting neurologists may290
see abnormal haematological investigations com-291
monly in these patients [39]. Therefore, even in the292
presence of ATTRm, AL-amyloidosis is possible and 293
vice versa. Hence, biopsies from different sites and 294
organs may be necessary and typing the amyloid fib- 295
rils is essential. 296
PROGNOSIS 297
Natural history studies of untreated ATTRm show 298
that late-onset ATTRV30M cases require a single 299
point stick to mobilise within 4 years of diagnosis 300
and a wheelchair within 7 years compared with 10 301
and 17 years, respectively, for patients with the classic 302
ATTRV30M presentation [40]. Cardiac biomarkers, 303
specifically N-terminal pro b-type natriuretic peptide 304
(NT-proBNP) is an independent predictor of mortal- 305
ity in AL, ATTRm and ATTRwt amyloidosis [41]. In 306
one study of 116 patients with untreated ATTRm, the 307
four year survival for ATTRV30M, ATTRT60A and 308
ATTRV122I, a predominantly cardiac phenotype, 309
was 79%, 40% and 16%, respectively [42]. There 310
is a significant difference between time to death in 311
the early compared to late-onset ATTRV30M, median 312
number of years is 16.9 vs. 6.8, respectively [40]. 313
SYMPTOMATIC TREATMENT 314
Patients with ATTRm require a multidisci- 315
plinary approach to their disease and symptomatic 316
treatment remains very important. Troublesome 317
symptoms include neuropathic pain, increasing 318
weakness, autonomic dysfunction, especially ortho- 319
static hypotension and altered bowel habit, and 320
cardiac symptoms of heart failure, arrhythmias or 321
heart block frequently needing a pacemaker or other 322
devices. When considering neuropathic pain agents, 323
care must be sought before using drugs that can 324
affect cardiac conduction or cause anticholinergic 325
side effects. 326
DISEASE MODIFYING THERAPIES 327
(SEE FIG. 1 FOR SUMMARY) 328
TTR exists as a stable tetramer, the dissociation of 329
which into monomers is required for amyloid depo- 330
sition. In addition, there is emerging evidence that 331
mutant TTR undergoes selective proteolytic cleavage 332
that predisposes the TTR tetramer to dissociate, par- 333
ticularly when exposed to shear forces such as those 334
in the heart and the carpal tunnel [43]. Current dis- 335
ease modifying therapies for ATTRm aim to either 336
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or to reduce mutant TTR production (liver transplan-338
tation or gene-silencing therapies).339
TREATMENTS AVAILABLE PRIOR TO 2018340
Liver transplantation341
The liver produces the majority of circulating342
TTR and therefore orthotopic liver transplantation343
(OLT) is an attractive treatment strategy for ATTRm344
as it significantly reduces the production of mutant345
protein. In carefully selected patients and experi-346
enced centres, the 10-year survival following OLT is347
75–78% in early-onset ATTRV30M [44]. Non-V30M348
patients, however, have a worse 5 and 10-year sur-349
vival following OLT of 59% and 44%, respectively,350
and late-onset ATTRV30M survival is significantly351
reduced compared to early-onset patients [44]. Other352
major prognostic factors for the success of OLT353
include age and duration of disease before transplan-354
tation. OLT rarely leads to regression of autonomic355
or peripheral neuropathy but does slow rate of356
progression, and in some cases, leads to stability.357
The limitations of OLT include the requirement for358
surgery and the associated mortality; the incidence of359
the main causes of death of ATTRm patients receiving360
OLT are comparable to patients being transplanted361
for other reasons, except for cardiac-related deaths362
which are much greater in the ATTRm population363
[44]. Also, there is ongoing synthesis of ATTRm from364
retinal pigment epithelium and choroid plexus, and365
the progression of ATTRwt deposition, especially in366
the myocardium, with up to 18.6% of patients devel-367
oping a cardiomyopathy post OLT [45]. Nevertheless,368
the experience with OLT has encouraged the devel-369
opment of other disease-modifying therapies aimed370
at reducing TTR production from the liver.371
Diﬂunisal372
Diflunisal is one of two TTR stabilisers used in373
clinical practice, the other being tafamidis. It is a374
nonsteroidal anti-inflammatory drug that binds to375
the thyroxine (T4) binding sites of tetrameric TTR376
thereby reducing dissociation and misfolding, and377
subsequent formation of amyloid fibrils [46]. The378
efficacy of difunisal, 500 mg a day, in patients with379
ATTRm and peripheral or autonomic neuropathy380
was demonstrated in a randomised, double-blind,381
placebo-controlled study conducted of 130 patients382
over 2 years. Diflunisal reduced the rate of pro-383
gression of neurological impairment and preserved384
quality of life (QOL) compared to placebo [47]. 385
Diflunisal is not licenced for ATTRm in Australia, 386
EU, UK or USA but off-label use is managed by 387
specialist centres. 388
Tafamidis 389
Tafamidis is a newer drug specifically developed to 390
stabilise the TTR tetramer by also binding to the T4 391
binding sites. Tafamidis has been approved in over 392
40 countries for treatment of ATTRm neuropathy. 393
In the UK, tafamidis is licenced for the treatment of 394
ATTRV30M with polyneuropathy, and it has orphan 395
drug status in the USA, EU and Australia [48]. 396
A multicentre, randomised, double-blind, placebo- 397
controlled study of tafamidis in 128 ATTRV30M 398
patients completed in May 2009 over 18 months 399
failed to meet its co-primary endpoints [49]. These 400
results, however, were confounded by a greater than 401
expected dropout in the treatment group due to the 402
availability of OLT. All participants who underwent 403
OLT were deemed to be non-responders in the inten- 404
tion to treat (ITT) analysis thereby under-powering 405
the trial. However, when the patients who completed 406
the study were analysed for the co-primary end- 407
points, 60% of the patients in the tafamidis group 408
were Neuropathy Impairment Score-Lower Limb 409
(NIS-LL) responders compared with 38.1% in the 410
placebo group, and the deterioration from baseline 411
in Norfolk Quality of Life Questionnaire-Diabetic 412
Neuropathy (Norfolk QOL-DN) questionnaire scores 413
was 0.1 point in the tafamidis group compared with 414
8.9 points in the placebo group [49]. A prospec- 415
tively planned, interim analysis was then conducted 416
on patients included in a 12-month, open-label exten- 417
sion of the above study and a single-arm, open label 418
study in 18 non-ATTRV30M patients [50]. Mean, 419
cumulative tafamidis exposure was 5.1 years in the 420
ATTRV30M patients who had 30 months of tafamidis 421
treatment, 3.5 years in the placebo arm who received 422
tafamidis in the open-label extension only, and 3.6 423
years in the non-ATTRV30M patients. All tafamidis 424
groups had slower rate of deterioration as mea- 425
sured by NIS-LL than natural history data [47]. A 426
30-month, phase 3, placebo-controlled, randomised 427
study published in 2018 investigated the efficacy and 428
safety of two doses of tafamidis, 20 mg and 80 mg 429
daily, in 441 patients with either ATTRwt or ATTRm 430
amyloidosis related cardiomyopathy [51]. The safety 431
profile was similar between the tafamidis and placebo 432
arms. All-cause mortality, rate of cardiovascular- 433
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capacity and QOL were lower in the tafamidis groups435
compared with the placebo group [51]. No serious436
adverse events were reported. This is promising for437
the treatment of the cardiac involvement in TTR438
amyloidosis.439
Doxycycline440
The combination of doxycycline and taurour-441
sodeoxycholic acid (TUDCA), a biliary acid, reduced442
TTR tissue deposition and SAP in ATTRV30M amy-443
loidosis mouse models [52]. The two agents are444
complementary in their targets, doxycycline causes445
disaggregation of amyloid deposits and TUDCA446
reduces accumulation of toxic TTR aggregates, but447
only works on non-fibrillar TTR deposits. A phase II448
open-label study completed in October 2015, evalu-449
ated the efficacy and safety of this combination over450
12 months in 20 patients, 17 patients with varying451
genotypes of ATTRm, and 3 with ATTRwt. 7 patients452
completed the 12-month treatment trial, 5 patients453
with a polyneuropathy had less than 2-point increase454
in NIS-LL, no patients had a worsening of modified455
Body Mass Index (mBMI) and no patients had a wors-456
ening of echocardiographic findings or heart failure457
symptoms. Doxycycline has orphan drug status in458
the EU through the European Medicines Authority459
(EMA). There is an ongoing phase 3 randomised460
study (ClinicalTrials.gov Identifier: NCT03481972)461
investigating doxycycline and TUDCA compared462
with standard therapy alone in ATTRm or ATTRwt463
cardiac amyloidosis.464
NEW TREATMENTS FROM TRIALS465
PUBLISHED IN 2018466
In 2018, two novel treatments for ATTRm467
amyloidosis related neuropathy, patisiran and inot-468
ersen (formerly IONIS-TTRRx/ISIS 420915) attained469
EMA and United States Food and Drug Admin-470
istration (FDA) approval following two successful471
phase-3 trials both published in New England Jour-472
nal of Medicine in July, 2018 [53–55]. Both drugs are473
genetic therapies that suppress ATTRwt and ATTRm474
synthesis in the liver through different but similar475
mechanisms and represent a paradigm shift in the476
management of this devastating disease.477
Patisiran478
Patisiran is a double-stranded synthetic ribonu-479
cleic acid molecule (RNAi) that targets hepatocytes480
in the liver and binds and activates the RNA-induced 481
silencing complex (RISC) leading to degradation of 482
the complementary, TTR messenger RNA (mRNA), 483
thereby reducing protein translation for both mutant 484
and wild-type TTR [53, 56] (See Fig. 1). Patisiran 485
is administered as an intravenous infusion every 21 486
days. 487
The APOLLO trial was a 18-month, randomised, 488
double-blind, multicentre, placebo-controlled trial in 489
225 patients (approximately 50% had ATTRV30M) 490
with ATTRm amyloidosis related peripheral neu- 491
ropathy [53]. This study included patients with prior 492
treatment with tetramer stabiliser and patients with 493
varying levels of disability, ranging from sensory 494
symptoms to the requirement of 1 or 2 sticks to 495
mobilise. All primary and secondary endpoints were 496
met; the primary endpoint was a change from baseline 497
in modified NIS + 7 (mNIS + 7) between groups. At 498
the end of 18 months, the least-squares mean change 499
in mNIS + 7 from baseline was –6.0 in the patisiran 500
group compared with 28.0 in the placebo arm. This 501
was significant for all subgroups, including age, geno- 502
type, clinical severity, previous tetramer stabiliser 503
usage, and presence of cardiomyopathy. Patisiran 504
resulted in a median of 81% decrease in serum TTR 505
from baseline which was consistent across age, gen- 506
der and genotype [53]. There were more infusion 507
related reactions in patients receiving patisiran but the 508
incidence of serious adverse events and deaths were 509
similar in the two groups [53]. 186 of the eligible 510
187 patients who completed the study were enrolled 511
in to the open-label extension study expected to be 512
completed in 2022. 513
Inotersen 514
Inotersen is a single-stranded deoxynucleotide 515
analogue (DNA) complementary to the sequence of 516
TTR pre-mRNA. The hybridisation of Inotersen to 517
the pre-mRNA induces RNase H endonuclease activ- 518
ity that cleaves the mRNA-ASO complex thereby 519
inhibiting production of mutant and wild-type TTR 520
protein [54–57] (See Fig. 1). Inotersen is adminis- 521
tered as a weekly subcutaneous injection. 522
The NEURO-TTR trial was a 15-month, 523
randomised, double-blind, multicentre, placebo- 524
controlled, trial in 172 patients (approximately 50% 525
had ATTRV30M) with ATTRm amyloidosis related 526
peripheral neuropathy [54]. This study included 527
patients with prior treatment with tetramer stabiliser 528
and patients with varying levels of disability. Inot- 529
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significantly less decline in the neuropathy and QOL531
measure in the inotersen group compared with the532
placebo group [54]. At the end of the 15 months,533
patients who received inotersen had an average534
increase of 5.8 points from baseline in mNIS + 7,535
compared with 25.5 points in the placebo group,536
and 1.0 point increase in the Norfolk QOL-DN537
score compared with 12.7 points in the placebo arm.538
This was significant across all of the subgroups,539
including genotype, age, race, previous exposure to540
TTR stabilisers and presence of cardiomyopathy.541
Patients receiving inotersen had a median reduction542
in serum TTR levels of 79% compared to baseline.543
Thrombocytopenia (platelet count less than 140,000544
per cubic millimetre) occurred in 54% of patients545
receiving inotersen resulting in a fatal intracranial546
haemorrhage in one patient. As a result, regular547
platelet monitoring was introduced, and no further548
episodes of severe thrombocytopenia were encoun-549
tered. Glomerulonephritis occurred in three patients550
in the inotersen group, two of which improved with551
corticosteroid treatment [54]. 139 patients completed552
the study period of which 135 were enrolled in to the553
open-label extension study expected to be completed554
in 2022.555
COMPLICATIONS AND LIMITATIONS OF556
DISEASE-MODIFYING TREATMENTS557
The name transthyretin reflects the numerous roles558
of the protein, TRANSport of THYroid hormones559
and RETINol-binding protein [58]. Patients receiving560
these treatments therefore require vitamin A sup-561
plementation and monitoring of thyroid function.562
In addition, gene silencing therapies have off-target563
effects and toxicities related to their chemical struc-564
ture, rather than the nucleotide sequence. These565
include activation of the complement and coagulation566
cascades when administered systemically which may567
explain the infusion-site reactions [59]. Inotersen and568
patisiran do not cross the blood-brain barrier, and569
therefore, synthesis of TTR by the choroid plexus570
is not affected by these treatments. This may prove571
to be relevant as the complications of ongoing CNS572
ATTRm deposition after OLT are well-documented.573
In one case study of 87 patients with ATTRV30M574
who had OLT, after an average of 14.6 years, 31%575
of patients had focal neurological episodes classi-576
fied clinically as focal seizures, aura-like episodes,577
or transient ischaemic attacks (MRI was contraindi-578
cated in all patients) and 5 patients had strokes [16].579
There are also reports of the development or progres- 580
sion of vitreous opacities (reflecting ongoing retinal 581
TTR production) and amyloid deposits in the pupil- 582
lary margin that could lead to glaucoma after OLT 583
[60]. 584
IMPLICATIONS FOR CLINICAL 585
PRACTICE 586
Early diagnosis of ATTRm is essential for timely 587
access to treatment. The availability of gene silencing 588
treatments raises issues regarding genetic screen- 589
ing and management of asymptomatic individuals. 590
For example, patients with ATTRm may develop 591
carpal tunnel syndrome with deposition of amyloid 592
in the flexor retinaculum several decades before the 593
development of a more generalised neuropathy or 594
cardiomyopathy. The optimum time to commence 595
treatment will need careful consideration and may 596
have some genotype/ethnic specificities. 597
CONCLUSION 598
The development and success of gene silencing 599
therapies in ATTRm amyloidosis is a breakthrough 600
for adult-onset, neurodegenerative diseases. Slowing 601
disease progression of this disabling, hereditary ill- 602
ness provides great hope for patients and treating 603
teams. There are uncertainties about the long-term 604
clinical benefit, when to initiate treatment and how 605
to incorporate these treatments in to the current 606
algorithms, however, they are a very welcome addi- 607
tion to presently available therapies. Accurate and 608
timely diagnosis of ATTRm amyloidosis has become 609
increasingly important as these therapies become 610
imminently available around the world. Efficiently 611
diagnosing patients requires first and foremost having 612
a high clinical suspicion, an awareness of the sys- 613
temic nature of the disease and an understanding of 614
the available diagnostic techniques. 615
ACKNOWLEDGMENTS 616
AMR is funded by a Wellcome Trust Postdoctoral 617
Fellowship for Clinicians (110043/Z/15/Z). 618
MMR is grateful to the Medical Research Coun- 619
cil (MRC), MRC Centre grant (G0601943), and 620
the National Institutes of Neurological Diseases and 621
Stroke and office of Rare Diseases (U54NS065712) 622
for their support. This research was also sup- 623











M. Kapoor et al. / Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis 9
University College London Hospitals Biomedical625
Research Centre.626
COMPETING INTERESTS627
AMR has received support from Alnylam UK Lim-628
ited to attend scientific meetings and an honorarium629
for speaking at a sponsored symposium. MMR has630
or has had consultancies with Alnylam Pharmaceu-631
ticals and Ionis Pharmaceuticals and MMR and ML632
were involved in the NEURO-TTR Trial (Clinical-633
Trials.gov Identifier: NCT01737398).634
MMR designed the study, MK collected data and635
wrote a draft of the paper. AMR and ML provided636
detailed written edits and multiple further drafts of the637
review for publication. All authors work fulfilled the638
following: substantial contributions to the conception639
or design of the work or the acquisition, analysis or640
interpretation of data; drafting the work or revising641
it critically for important intellectual content; gave642
final approval of the version published; agreed to be643
accountable for all aspects of the work in ensuring644
that questions related to the accuracy or integrity of645
any part of the work are appropriately investigated646
and resolved.647
REFERENCES648
[1] Lim KH, Dasari AKR, Hung I, Gan Z, Kelly JW, Wemmer649
DE. Structural Changes Associated with Transthyretin Mis-650
folding and Amyloid Formation Revealed by Solution and651
Solid-State NMR. Biochemistry. 2016;55(13):1941-4.652
[2] Do Amaral B, Coelho T, Sousa A, Guimara˜es A. Usefulness653
of labial salivary gland biopsy in familial amyloid polyneu-654
ropathy Portuguese type. Amyloid. 2009;16(4):232-8.655
10.3109/13506120903421850656
[3] Lechapt-Zalcman E, Authier FJ, Creance A, Voisin MC,657
Gherardi RK. Labial salivary gland biopsy for diagno-658
sis of amyloid polyneuropathy. Muscle and Nerve. 1999;659
22(1):105-7.660
[4] Adams D, Suhr OB, Hund E, Obici L, Tournev I, Camp-661
istol JM, et al. First European consensus for diagnosis,662
management, and treatment of transthyretin familial amy-663
loid polyneuropathy. Curr Opin Neurol. 2016;29:S14-26.664
10.1097/WCO.0000000000000289665
[5] The´audin M, Lozeron P, Algalarrondo V, Lacroix C, Cauquil666
C, Labeyrie C, et al. Upper limb onset of hereditary667
transthyretin amyloidosis is common in non-endemic areas.668
Eur J Neurol. 2018;ene.13845. 10.1111/ene.13845669
[6] Carr AS, Pelayo-Negro AL, Jaunmuktane Z, Scalco RS,670
Hutt D, Evans MRB, et al. Transthyretin V122I amyloidosis671
with clinical and histological evidence of amyloid neuropa-672
thy and myopathy. Neuromuscul Disord. 2015;25(6):511-5.673
10.1016/j.nmd.2015.02.001674
[7] Plante´-Bordeneuve V, Said G. Familial amyloid polyneu-675
ropathy. Lancet Neurol. 2011;10(12):1086-97. 10.1016/S14676
74-4422(11)70246-0677
[8] Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Mer- 678
lini G, Saraiva MJM, et al. Amyloid fibril proteins 679
and amyloidosis: Chemical identification and clinical 680
classification International Society of Amyloidosis 2016 681
Nomenclature Guidelines. Amyloid. 2016;23(4):209-13. 682
10.1080/13506129.2016.1257986 683
[9] Plante´-Bordeneuve V, Ferreira A, Lalu T, Zaros C, 684
Lacroix C, Adams D, et al. Diagnostic pitfalls in sporadic 685
transthyretin familial amyloid polyneuropathy (TTR-FAP). 686
Neurology. 2007;69(7):693-8. 687
[10] Parman Y, Adams D, Obici L, Gala´n L, Guergueltcheva V, 688
Suhr OB, et al. Sixty years of transthyretin familial amyloid 689
polyneuropathy (TTR-FAP) in Europe. Curr Opin Neurol. 690
2016;29:S3-13. 10.1097/WCO.0000000000000288 691
[11] Gertz MA. Immunoglobulin light chain amyloidosis: 2018 692
Update on diagnosis, prognosis, and treatment. Am J Hema- 693
tol. 2018;93(9):1169-80. 10.1002/ajh.25149 694
[12] Liewluck T, Milone M. Characterization of isolated amyloid 695
myopathy. Eur J Neurol. 2017;24(12):1437-45. 696
[13] Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, 697
Adams D, Suhr OB. Evolving landscape in the manage- 698
ment of transthyretin amyloidosis. Ann Med. 2015;47(8): 699
625-38. 700
[14] Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, Ando Y. 701
Diagnosis and management of transthyretin familial amy- 702
loid polyneuropathy in Japan: Red-flag symptom clusters 703
and treatment algorithm. Orphanet J Rare Dis. 2018;13(1):6. 704
10.1186/s13023-017-0726-x 705
[15] McColgan P, Viegas S, Gandhi S, Bull K, Tudor R, Sheikh 706
F, et al. Oculoleptomeningeal Amyloidosis associated with 707
transthyretin Leu12Pro in an African patient. J Neurol. 708
2015;262(1):228-34. 709
[16] Maia LF, Magalha˜es R, Freitas J, Taipa R, Pires MM, Oso´rio 710
H, et al. CNS involvement in V30M transthyretin amyloido- 711
sis: Clinical, neuropathological and biochemical findings. J 712
Neurol Neurosurg Psychiatry. 2015;86(2):159-67. 713
[17] Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, 714
Salvi F, et al. Disease profile and differential diagnosis 715
of hereditary transthyretin-related amyloidosis with exclu- 716
sively cardiac phenotype: An Italian perspective. Eur Heart 717
J. 2013;34(7):520-8. 10.1093/eurheartj/ehs123 718
[18] Jacobson D, McFarlin D, Kane I, Buxbaum J. Transthyretin 719
Pro55, a variant associated with early-onset, aggressive, 720
diffuse amyloidosis with cardiac and neurologic involve- 721
ment. Hum Genet. 1992;89(3):353-6. 10.1007/BF00220 722
559 723
[19] Pearson KT, Vota S. Amyloidosis and its management: 724
Amyloid neuropathies. Curr Probl Cancer. 2016;40(5- 725
6):198-208. 726
[20] Gonzalez-Duarte A. Autonomic involvement in hered- 727
itary transthyretin amyloidosis (hATTR amyloidosis). 728
Clin Auton Res. 2018;(0123456789). 10.1007/s10286-018- 729
0514-2 730
[21] Alavi A, French LE, Davis MD, Brassard A, Kirsner 731
RS. Pyoderma Gangrenosum: An Update on Pathophys- 732
iology, Diagnosis and Treatment. Am J Clin Dermatol. 733
2017;18(3):355-72. 734
[22] Nichols WC, Gregg RE, Brewer HB, Benson MD. A muta- 735
tion in apolipoprotein A-I in the Iowa type of familial 736
amyloidotic polyneuropathy. Genomics. 1990;8(2):318-23. 737
10.1016/0888-7543(90)90288-6 738
[23] Perfetto F, Moggi-Pignone A, Livi R, Tempestini A, 739
Bergesio F, Matucci-Cerinic M. Systemic amyloidosis: 740












10 M. Kapoor et al. / Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis
[24] Wechalekar AD, Gillmore JD, Hawkins PN. Sys-743
temic amyloidosis. Lancet. 2016;387(10038):2641-54.744
10.1016/S0140-6736(15)01274-X745
[25] Reilly MM, Staunton H, Harding AE. Familial amyloid746
polyneuropathy (TTR ala 60) in north west Ireland: A clini-747
cal, genetic, and epidemiological study. J Neurol Neurosurg748
Psychiatry. 1995;59(1):45-9.749
[26] Terkelsen AJ, Karlsson P, Lauria G, Freeman R, Finnerup750
NB, Jensen TS. The diagnostic challenge of small fibre751
neuropathy: Clinical presentations, evaluations, and causes.752
Lancet Neurol. 2017;16(11):934-44. 10.1016/S1474-4422753
(17)30329-0754
[27] Lozeron P, Mariani L-L, Dodet P, Beaudonnet G, The´audin755
M, Adam C, et al. Transthyretin amyloid polyneuropathies756
mimicking a demyelinating polyneuropathy. Neurology.757
2018;91(2):e143-52. 10.1212/WNL.0000000000005777758
[28] Low PA, Tomalia VA, Park K-J. Autonomic Function Tests:759
Some Clinical Applications. J Clin Neurol. 2013;9(1):1.760
10.3988/jcn.2013.9.1.1761
[29] Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch762
E, Biaggioni I, et al. Consensus statement on the defini-763
tion of orthostatic hypotension, neurally mediated syncope764
and the postural tachycardia syndrome. Clin Auton Res.765
2011;21(2):69-72.766
[30] Weimer LH. Autonomic Testing. Neurologist. 2010;16(4):767
215-22. 10.1097/NRL.0b013e3181cf86ab768
[31] Sekijima Y. Transthyretin (ATTR) amyloidosis: Clin-769
ical spectrum, molecular pathogenesis and disease-770
modifying treatments. J Neurol Neurosurg Psychiatry.771
2015;86(9):1036-43. 10.1136/jnnp-2014-308724772
[32] Simmons Z, Specht CS. The neuromuscular manifestations773
of amyloidosis. J Clin Neuromuscul Dis. 2010;11(3):145-774
57.775
[33] Leung N, Nasr SH, Sethi S. How I Treat amyloidosis:776
The importance of accurate diagnosis and amyloid typing.777
Blood. 2012;120(16):3206-13. 10.1182/blood-2012-03-778
413682779
[34] Sachchithanantham S, Wechalekar AD. Imaging in systemic780
amyloidosis. Br Med Bull. 2013;107(1):41-56.781
[35] Hazenberg BPC, Van Rijswijk MH, Piers DA, Lub-De782
Hooge MN, Vellenga E, Haagsma EB, et al. Diagnostic783
performance of123I-labeled serum amyloid P component784
scintigraphy in patients with amyloidosis. Am J Med.785
2006;119(4).786
[36] Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato787
C, Leone O, et al. Usefulness and limitations of99mTc-3, 3-788
diphosphono-1, 2-propanodicarboxylic acid scintigraphy in789
the aetiological diagnosis of amyloidotic cardiomyopathy.790
Eur J Nucl Med Mol Imaging. 2011;38(3):470-8.791
[37] Cortese A, Vegezzi E, Lozza A, Alfonsi E, Montini792
A, Moglia A, et al. Diagnostic challenges in hereditary793
transthyretin amyloidosis with polyneuropathy: Avoiding794
misdiagnosis of a treatable hereditary neuropathy. J Neurol795
Neurosurg Psychiatry. 2017;88(5):457-8.796
[38] Conceic¸a˜o I, Gonza´lez-Duarte A, Obici L, Schmidt HHJ,797
Simoneau D, Ong ML, et al. Red-flag symptom clusters in798
transthyretin familial amyloid polyneuropathy. J Peripher799
Nerv Syst. 2016;21(1):5-9.800
[39] Phull P, Sanchorawala V, Connors LH, Doros G,801
Ruberg FL, Berk JL, et al. Monoclonal gammopathy of802
undetermined significance in systemic transthyretin amy-803
loidosis (ATTR). Amyloid. 2018;25(1):62-7. 10.1080/1350804
6129.2018.1436048805
[40] Mariani LL, Lozeron P, The´audin M, Mincheva Z, Sig-806
nate A, Ducot B, et al. Genotype-phenotype correlation807
and course of transthyretin familial amyloid polyneu- 808
ropathies in France. Ann Neurol. 2015;78(6):901-16. 809
10.1002/ana.24519 810
[41] Damy T, Jaccard A, Guellich A, Lavergne D, Galat A, Deux 811
JF, et al. Identification of prognostic markers in transthyretin 812
and AL cardiac amyloidosis*. Amyloid. 2016;23(3):194- 813
202. 814
[42] Arruda-Olson AM, Zeldenrust SR, Dispenzieri A, Gertz 815
MA, Miller FA, Bielinski SJ, et al. Genotype, echocar- 816
diography, and survival in familial transthyretin amy- 817
loidosis. Amyloid. 2013;20(4):263-8. 10.3109/13506129. 818
2013.845745 819
[43] Marcoux J, Mangione PP, Porcari R, Degiacomi MT, 820
Verona G, Taylor GW, et al. A novel mechano-enzymatic 821
cleavage mechanism underlies transthyretin amyloidoge- 822
nesis. EMBO Mol Med. 2015;7(10):1337-49. 10.15252/ 823
emmm.201505357 824
[44] Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, 825
Stangou A, Pena JR, et al. Liver Transplantation for Hered- 826
itary Transthyretin Amyloidosis: After 20 Years Still the 827
Best Therapeutic Alternative? Transplantation. 2015;99(9): 828
1847-54. 829
[45] Yamamoto S, Wilczek HE, Nowak G, Larsson M, Oksa- 830
nen A, Iwata T, et al. Liver transplantation for familial 831
amyloidotic polyneuropathy (FAP): A single-center experi- 832
ence over 16 years. Am J Transplant. 2007;7(11):2597-604. 833
10.1111/j.1600-6143.2007.01969.x 834
[46] Adams D, Cauquil C, Labeyrie C, Beaudonnet G, Algalar- 835
rondo V, The´audin M. TTR kinetic stabilizers and TTR gene 836
silencing: A new era in therapy for familial amyloidotic 837
polyneuropathies. Expert Opin Pharmacother. 2016;17(6): 838
791-802. 10.1517/14656566.2016.1145664 839
[47] Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust 840
SR, Yamashita T, et al. Repurposing diflunisal for famil- 841
ial amyloid polyneuropathy: A randomized clinical trial. 842
JAMA - J Am Med Assoc. 2013;310(24):2658-67. 10.1001/ 843
jama.2013.283815 844
[48] Joint Formulary Committee. Tafamidis [Internet]. British 845
National Formulary (BNF). 846
[49] Coelho T, Maia LF, Da Silva AM, Cruz MW, 847
Plante´-Bordeneuve V, Lozeron P, et al. Tafamidis for 848
transthyretin familial amyloid polyneuropathy: A ran- 849
domized, controlled trial. Neurology. 2012;79(8):785-92. 850
10.1212/WNL.0b013e3182661eb1 851
[50] Barroso FA, Judge DP, Ebede B, Li H, Stewart M, Amass 852
L, et al. Long-term safety and efficacy of tafamidis for the 853
treatment of hereditary transthyretin amyloid polyneuropa- 854
thy: Results up to 6 years. Amyloid. 2017;24(3):194-204. 855
10.1080/13506129.2017.1357545 856
[51] Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Mer- 857
lini G, Waddington-Cruz M, et al. Tafamidis Treatment 858
for Patients with Transthyretin Amyloid Cardiomyopa- 859
thy. N Engl J Med. 2018;379(11):NEJMoa1805689. 860
10.1056/NEJMoa1805689 861
[52] Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva 862
MJ. Synergy of combined Doxycycline/TUDCA treat- 863
ment in lowering Transthyretin deposition and associated 864
biomarkers: Studies in FAP mouse models. J Transl Med. 865
2010;8(1):74. 10.1186/1479-5876-8-74 866
[53] Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang C-C, 867
Ueda M, Kristen AV, et al. Patisiran, an RNAi Therapeutic, 868
for Hereditary Transthyretin Amyloidosis. N Engl J Med. 869
2018;379(1):11-21. 10.1056/NEJMoa1716153 870
[54] Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, 871











M. Kapoor et al. / Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis 11
with Hereditary Transthyretin Amyloidosis. N Engl J Med.873
2018;379(1):22-31. 10.1056/NEJMoa1716793874
[55] Grosenbach DW, Honeychurch K, Rose EA, Chinsangaram875
J, Frimm A, Maiti B, et al. Oligonucleotide Drugs for876
Transthyretin Amyloidosis. N Engl J Med. 2018;379(21):877
2085-6. 10.1056/NEJMc1810994878
[56] Rossor AM, Reilly MM, Sleigh JN. Antisense oligonu-879
cleotides and other genetic therapies made simple. Pract880
Neurol. 2018;18(2):126-31. 10.1136/practneurol-2017-001881
764882
[57] Ghosh R, Tabrizi SJ. Gene suppression approaches to883
neurodegeneration. Alzheimer’s Res Ther. 2017;9(1):1-13.884
10.1186/s13195-017-0307-1885
[58] Alshehri B, D’Souza DG, Lee JY, Petratos S, Richardson 886
SJ. The diversity of mechanisms influenced by transthyretin 887
in neurobiology: Development, disease and endocrine dis- 888
ruption. J Neuroendocrinol. 2015;27(5):303-23. 10.1111/ 889
jne.12271 890
[59] Jason TLH, Koropatnick J, Berg RW. Toxicology 891
of antisense therapeutics. Toxicol Appl Pharmacol. 892
2004;201(1):66-83. 10.1016/j.taap.2004.04.017 893
[60] Ando Y, Terazaki H, Nakamura M, Ando E, Haraoka K, 894
Yamashita T, et al. A different amyloid formation mecha- 895
nism: De novo oculoleptomeningeal amyloid deposits after 896
liver transplantation. Transplantation. 2004;77(3):345-9. 897
